Australia markets closed

Exact Sciences Corporation (EXAS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
131.30-3.52 (-2.61%)
At close: 4:00PM EST

128.10 -3.20 (-2.44%)
Pre-market: 5:34AM EST

Full screen
Trade prices are not sourced from all markets
Previous close134.82
Open132.56
Bid0.00 x 1300
Ask0.00 x 1000
Day's range126.00 - 133.65
52-week range35.25 - 159.54
Volume1,635,190
Avg. volume1,828,468
Market cap22.202B
Beta (5Y monthly)1.47
PE ratio (TTM)N/A
EPS (TTM)-5.61
Earnings date04 May 2021 - 10 May 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est173.00
  • Exact Sciences to participate in March investor conferences
    PR Newswire

    Exact Sciences to participate in March investor conferences

    Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.

  • Adding $5,000 to These 2 Top Stocks Could Make You Richer in 2021 (and Beyond)
    Motley Fool

    Adding $5,000 to These 2 Top Stocks Could Make You Richer in 2021 (and Beyond)

    According to the U.S. Centers for Disease Control and Prevention (CDC), cancer is the second-leading cause of death in the U.S. (behind heart disease), claiming 599,601 lives in 2019. One area where scientists are making substantial headway is in the field of cancer diagnostics. Two cancer diagnostics-focused stocks worth buying are Exact Sciences (NASDAQ: EXAS) and Guardant Health (NASDAQ: GH).

  • Why Exact Sciences Stock Sank Today
    Motley Fool

    Why Exact Sciences Stock Sank Today

    Shares of Exact Sciences (NASDAQ: EXAS) were sinking 9.2% as of 2:52 p.m. EST on Wednesday. Exact Sciences announced Q4 revenue of $466.3 million, up nearly 58% year over year and above the Wall Street consensus estimate of $446 million. Exact Sciences' research and development expense was much greater than what analysts projected due to the acquisition of Base Genomics.